A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence.
about
Opioid agonist treatment for pharmaceutical opioid dependent peopleBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependencePharmacological therapies for maintenance treatments of opium dependenceBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependenceOpioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteriaImpact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysisThe effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trialPractical considerations for the clinical use of buprenorphine.Opioid dependence treatment: options in pharmacotherapy.Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.Buprenorphine for opioid dependenceThe history of the development of buprenorphine as an addiction therapeutic.Opioid dependence treatment, including buprenorphine/naloxone.Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence.A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions.The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.Comparison of buprenorphine treatment for opioid dependence in 3 settingsIllicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.Bupreorphine:a new pharmacotherapy for opioid addictions treatment.Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain.Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatmentBuprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.Adoption of medications in substance abuse treatment: priorities and strategies of single state authoritiesMoving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphineBuprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors.Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphineThe clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.Treatment outcome for flexible dosing buprenorphine maintenance treatment.Effect of buprenorphine dose on treatment outcome.A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation.
P2860
Q24185775-C8FD74ED-8D33-4104-9A89-3DF4C45DDE09Q24200539-E3B270C6-BBAD-4CE1-A165-78433676F7E2Q24201615-B4B5B951-8BF1-4E27-909F-693F4F352B83Q24243180-F4085F15-5C6D-4312-A5C8-E8D472ECAD7BQ26778626-83FC8026-EB46-4F80-B317-324BFFB301A0Q26785010-6FD3298D-DEDE-4AF7-8681-C9C6FDCEE49CQ30490602-F13A68CA-DCAF-498F-80DF-7E56FA7224F0Q33700165-50375E33-B3C3-4421-B8EF-C5BCF7313389Q33774853-E599E042-C5E4-45CB-A985-36A524A785DFQ33868638-329B6A34-B34E-4C84-881D-BCC1ADCF87A1Q34033200-92799050-B3AA-4FFE-8DC5-6924E965C433Q34081656-B304DA03-6D59-4C96-BFA1-437A7A3C3F2BQ34119459-9DD6B137-42F2-4894-87BB-9B059B72DBE8Q34248057-57E65880-9E74-4F30-8CAA-9B790B5B5797Q34533873-C55D2CDD-6853-4EC4-B2C6-E8B4A11AA191Q34615753-CFBFA842-7FFD-4A26-9108-A1CF7C026D8EQ34620483-648E0BE7-8A57-42AB-9369-16960D2131DBQ34850334-13B4635B-1CB9-4133-8311-7CA15D56AA9AQ35023292-291CF0CB-1703-410B-81CA-93F73D7D9E03Q35575641-B8F72F75-BB30-46C8-BFB6-8E19E45A1A6DQ35586209-94FA045E-5C21-41A4-8C5B-794FF15C837DQ35686969-9AFE89D4-1B6D-4B06-8789-F7E45BFF9EBEQ35687716-F20ADA6A-3D78-4C3C-9F40-A24DBC8AAA64Q35748679-5A3916F1-3217-4CFC-AFB2-EC5A07F237BFQ35800468-17E3A525-ADF7-48FF-A7A9-2E7544E8C786Q35886112-D7743C90-5194-448D-9F54-4B1023B493C8Q35980664-B944CE99-4488-45F7-8287-23DE1B480FB8Q36110773-DA4CA19B-63C6-4518-8383-DBC095DC59ACQ36345193-EDDC4091-AE31-4C56-99E7-2613A6F953F5Q36364490-C945D1A4-DF6A-4862-878E-53CDB7F3FF33Q36738043-AC3BC56F-6AE5-4568-90DB-2122548D05F1Q36806539-AE645538-B875-4C7D-9379-2B1519766CF8Q36821137-FF28C922-1E04-42C7-9EE0-39172DE512A8Q36984354-ADDB43CB-5568-473D-A8D3-02B63C10BA0DQ37062538-EC17C35F-F87B-4E1C-98F4-8C340A4585E4Q37073555-E744771B-36F1-4385-A345-A57306CF4BDEQ37587221-356E5A5B-9895-4C9C-BE25-8AE0322CF8F9Q37969169-B1E6F144-BF6F-4BB8-944C-228DC13BE377Q37987271-5B7AB378-3C0F-4841-8B1C-951926755FF7Q38016946-4BA17516-F270-4672-A199-D64BE2FA3FCE
P2860
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
A placebo controlled clinical ...... eatment for opioid dependence.
@en
A placebo controlled clinical ...... eatment for opioid dependence.
@nl
type
label
A placebo controlled clinical ...... eatment for opioid dependence.
@en
A placebo controlled clinical ...... eatment for opioid dependence.
@nl
prefLabel
A placebo controlled clinical ...... eatment for opioid dependence.
@en
A placebo controlled clinical ...... eatment for opioid dependence.
@nl
P2093
P1476
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence
@en
P2093
E C Strain
G E Bigelow
I A Liebson
M L Stitzer
R E Johnson
P356
10.1016/0376-8716(95)01186-2
P577
1995-11-01T00:00:00Z